Becton Dickinson and Co (BDX) Osake Kurssi
Becton Dickinson and Co Kurssi
Liikevaihto on kasvanut 7,3 % vuodessa viimeisten 19 vuoden aikana 21,84 Mrd. USD:een. Osakekohtainen tulos on kasvanut 3,7 % vuodessa viimeisten 19 vuoden aikana. Becton Dickinson and Con nettomarginaali on nyt 7,7 %, laskenut 10,9 %:sta muutama vuosi sitten. Becton Dickinson and Con osinkotuotto on tällä hetkellä noin 2,29 %. Jakosuhde on noin 71 % tuloksesta. Osinko on kasvanut 8,5 % vuodessa viimeisten 19 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 190,00 USD, eli yli nykyhintaa 4,2 %. 21 analyytikosta 12 suosittaa ostoa — kokonaiskonsensus on Osta.
Becton Dickinson and Co osakekurssi
Becton Dickinson and Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Becton Dickinson and Co -osakkeesta
Becton Dickinson and Co (BD) operates under a diversified business model. As a leading global medical technology company, BD focuses on improving healthcare delivery by developing innovative solutions. The company's business model revolves around three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical offers a range of medical devices, such as injection systems and infusion therapy products, to enhance patient care. BD Life Sciences focuses on research and clinical laboratories, providing products for sample management and diagnostics. BD Interventional specializes in devices for minimally invasive procedures, contributing to improved patient outcomes. Becton Dickinson and Co's business model aims to address critical healthcare challenges by delivering reliable and effective solutions.
Becton Dickinson and Co is primarily active in the healthcare industry, specifically focusing on medical technology and devices.
The main competitors of Becton Dickinson and Co in the market are Thermo Fisher Scientific Inc., Cardinal Health Inc., and Johnson & Johnson.
Becton Dickinson and Co, commonly known as BD, is a leading global medical technology company. Founded in 1897, BD has a rich history and a strong reputation in the healthcare industry. The company specializes in medical devices, instrument systems, and reagents used by healthcare professionals for diagnostic and therapeutic purposes. With over a century of experience, BD has grown to become a trusted provider of innovative solutions that improve the quality of patient care. Headquartered in Franklin Lakes, New Jersey, BD operates in more than 190 countries worldwide, serving hospitals, laboratories, healthcare professionals, and patients with its diverse portfolio of products.
Becton Dickinson and Co has achieved several significant milestones throughout its history. The company pioneered the development of the first-ever sterile disposable syringe, which revolutionized healthcare practices worldwide. They also introduced the first medical-grade plastic blood collection tube, improving patient safety and sample integrity. Becton Dickinson and Co expanded its global presence by acquiring C.R. Bard, a leading medical technology company specializing in vascular, urology, and oncology products. This strategic move enhanced their product portfolio and market reach. Furthermore, the company has consistently focused on innovation, manufacturing high-quality medical devices, laboratory equipment, and diagnostic tools. Becton Dickinson and Co continues to drive advancements in healthcare, improving patient outcomes globally.
Becton Dickinson and Co is primarily present in numerous countries and regions across the globe. The company operates in various key markets, including the United States, Europe, Asia-Pacific, Latin America, and the Middle East. With its strong global presence, Becton Dickinson and Co has established a solid market foothold, allowing it to cater to a diverse range of customers and meet their healthcare needs effectively.
Becton Dickinson and Co represents a strong commitment to quality and innovation in the healthcare industry. The company's corporate philosophy revolves around improving patient outcomes through advanced medical technologies and solutions. By prioritizing patient safety and healthcare efficiency, Becton Dickinson has established itself as a leading provider of medical devices, diagnostic systems, and pharmaceutical systems. Their values include integrity, collaboration, and customer focus, emphasizing the importance of ethical behavior, teamwork, and meeting customer needs. Becton Dickinson and Co's dedication to advancing healthcare makes it a trusted partner for healthcare professionals worldwide.
Analyytikot asettavat tällä hetkellä Becton Dickinson and Co-osakkeelle keskimääräisen tavoitehinnan 186,88 USD (mediaani: 190,00 USD), mikä merkitsee +2,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 21 analyytikkoarvioon.
21 analyytikkoa arvioi tällä hetkellä Becton Dickinson and Co-osaketta: 12 suosittaa ostoa, 9 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Becton Dickinson and Co-yhtiöltä 19,29 Mrd. USD liikevaihtoa ja 12,83 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Becton Dickinson and Co-osake noteerataan hintaan 162,76 EUR (182,42 USD).
Becton Dickinson and Co-osake (BDX) on listattuna 10 pörssissä, muun muassa: NYSE (BDX), London (0R19.L), SIX (Zürich) (BDX.SW), XETRA (BOX.DE), Frankfurt (BOX.F), München (BOX.MU), Düsseldorf (BOX.DU), Wien (BDX.VI).
Becton Dickinson and Co. (BD) is a global leading medical technology company that specializes in diagnostics, instruments, and systems for medical therapy, laboratories, and life science research. The company is headquartered in New Jersey, USA, and operates in over 190 countries worldwide. The company is divided into three main business segments: BD Medical, BD Life Sciences, and BD Interventional. Each of these segments offers various products and services tailored to the needs of customers in the respective industries. BD Medical specializes in the development, manufacturing, and marketing of medical devices, insulin syringes, needles, and clinical diagnostic instruments. The goal of BD Medical is to help patients improve healthcare and reduce costs through innovative solutions. Some well-known products from BD Medical include BD Vacutainer blood collection systems, BD BACTEC systems for bacterial culture, BD Nexiva Closed I.V. catheter, and BD insulin syringes. BD Life Sciences specializes in the areas of biosciences and research. The company offers a wide range of products and services, including instruments and reagents for molecular biology, infectious diseases, and cancer research. BD Life Sciences supports scientists worldwide in the search for new diagnostic and treatment methods for diseases. Some well-known products from BD Life Sciences include BD FACSFlow Sheath Fluid, BD MAX systems for PCR amplification of DNA and RNA, and BD SurePath vials for cytological diagnosis. BD Interventional offers a variety of products and solutions for interventional medical technology. Key products from BD Interventional include catheters, stents, dilators, guide wires, and implantable devices such as pacemakers and defibrillators. The goal of BD Interventional is to provide surgeons and other medical professionals with the best possible tools and devices to safely and effectively treat patients and minimize the risk of complications. BD is also active in other business segments, such as the oil and gas industry and environmental analysis. The company also offers a wide range of professional services, training, and support to help professionals and customers effectively utilize BD's products and solutions. BD relies on continuous innovation to continuously improve its products and always provide customers with the best quality and performance. The company invests in research and development every year and collaborates closely with medical professionals and scientists to meet the demands of markets and customers. In summary, BD is a leading medical technology company focused on providing innovative products and solutions for the biosciences, clinical diagnostics, interventional medicine, and other industries. The company relies on a wide range of products and services, as well as continuous innovation and collaboration. With its global presence and commitment to quality and performance, BD positions itself as one of the key providers for the medical industry.
odotettu liikevaihto Becton Dickinson and Co on 19,29 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Becton Dickinson and Co on 3,66 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Becton Dickinson and Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 14,22. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Becton Dickinson and Co-osakkeen arvostusta.
Becton Dickinson and Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,70. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Becton Dickinson and Co-osakkeen arvostuskennuslukuna.
Becton Dickinson and Co:n Eulpool-laatuscore on 4/10.
Becton Dickinson and Co:n ISIN on US0758871091. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Becton Dickinson and Co:n WKN on 857675. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Becton Dickinson and Co:n ticker on BDX. Tämä pörssinoteeraus käytetään Becton Dickinson and Co-osakkeiden kauppaan pörssissä.
Becton Dickinson and Co osake
Becton Dickinson and Co vertaisryhmä
Becton Dickinson and Co Ticker
Becton Dickinson and Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Becton Dickinson and Co:sta
Meidän osakeanalyysimme Becton Dickinson and Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Becton Dickinson and Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: